OncoMatch/Clinical Trials/NCT07486713
Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies
Is NCT07486713 recruiting? Yes, currently enrolling (May 2026). This Phase 4 trial studies multiple treatments including Olutasidenib and CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates for aml (acute myeloid leukemia).
Treatment: Olutasidenib · CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A4, and OATP1B1 Probe Substrates — A open-label drug-drug interaction (DDI) study to evaluate the effects of olutasidenib on the pharmacokinetics (PK) of a CYP450 and OATP1B1 probe substrate cocktail in participants with IDH1 mutation-positive malignancies.
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Myeloid Leukemia
Glioblastoma
Cholangiocarcinoma
Tumor Agnostic
Biomarker criteria
Required: IDH1 mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: olutasidenib (olutasidenib)
Exception: must not have received olutasidenib within the 2 weeks prior to the first dose of study drug
Patient should not have received olutasidenib within the 2 weeks prior to the first dose of study drug.
Cannot have received: anticancer treatment
Exception: minimum time must have elapsed from prior anticancer treatment to first dose of study treatment: cancer therapies, including chemotherapy, radiation, biologics or kinase inhibitors, or major surgery within 4 weeks prior to the first scheduled study treatment; for longer acting agents such as nitrosourea, mitomycin or antibody therapies, a minimum of 6 weeks.
Cancer therapies, including chemotherapy, radiation, biologics or kinase inhibitors, or major surgery within 4 weeks prior to the first scheduled study treatment; for longer acting agents such as nitrosourea, mitomycin or antibody therapies, a minimum of 6 weeks.
Cannot have received: investigational agent
Exception: within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent)
Use of investigational agents within 4 weeks prior to study enrollment (within 6 weeks if the treatment was with a long-acting agent).
Lab requirements
Kidney function
creatinine clearance ≥ 30 ml/min using cockcroft-gault equation
Liver function
ast and alt values ≤ 2.5 × uln; bilirubin ≤ 1.5× uln (≤ 3 × uln in patients with gilbert syndrome) or ≤ 3 × uln for patients with aml involvement
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCI Irvine Health · Orange, California
- New York Presbyterian Hospital-Columbia University Medical Center · New York, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify